A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

A larger waist circumference is associated with a higher risk of all-cause mortality and decreased life expectancy. Meanwhile ...

Eli Lilly said that it planned to seek regulatory approval to market the drug for weight loss later this year, and early next year for diabetes. The F.DA. could take months and possibly longer to ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

As Stat reports, the federal judge's ruling means patients will lose access to less-expensive versions of Eli Lilly's weight loss drug, as well as diabetes treatment Mounjaro, from compounding ...

Drugmaker Eli Lilly ... a huge trend in weight loss drugs. And orforglipron looks like it could be a game-changer, driving even more growth for Lilly. Geoffrey Seiler has no position in any ...

Could the long-running obesity drugs leadership anchored by the Denmark-headquartered Novo Nordisk (NVO) be finally coming to an end? While arch rival Eli Lilly ... its oral weight loss pill ...

Branded drug manufacturers, including Eli Lilly and Company (Eli Lilly), have been pursuing various legal actions against compounding pharmacies ...

Big Pharma has put a Houston pharmacy squarely in the crosshairs of its quest to weed out copycat versions of wildly popular diabetes and weight loss drugs. Eli Lilly, the maker of the diabetes ...